ORPHA:172
Progressive familial intrahepatic cholestasis
Also known as: PFIC
Publications
2,892
Trials
13
Interventional, condition-specific
Researchers
1,142
Distinct authors in sample
Gene link
ABCB11, ATP8B1, PLEC
Strong
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
familial intrahepatic cholestasis (PFIC) refers to a heterogeneous group of disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015762
- UMLS:C0268312
- NCIT:C84453
Additional Mondo synonyms (1)
cholestasis, progressive familial intrahepatic
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Strong — ABCB11, ATP8B1, PLEC
- LiteraturePresent
2,892 matched papers (1,824 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
13 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ABCB11, ATP8B1, PLEC).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,892
2,892 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,892 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,824 in the last 10 years · low confidence
Phrase hits: 2,892 · MeSH hits: 0
Who's working on it?
1,142
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Verkade HJ6 papers · 2026
Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Papers in Europe PMC - 02Gonzales E4 papers · 2025
Université Paris-Saclay, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, FHU Hepatinov, 91400 Orsay, France.
Papers in Europe PMC - 03Kuipers F4 papers · 2026
Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Papers in Europe PMC - 04Sciveres M4 papers · 2025
Pediatric Department and Transplantation, ISMETT IRCCS, Palermo, Italy.
Papers in Europe PMC - 05Chen HL3 papers · 2025
Department of Pediatrics, National Taiwan University Children's Hospital, Taipei, Taiwan.
Papers in Europe PMC - 06Dalgıç B3 papers · 2025
Department of Pediatric Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey.
Papers in Europe PMC - 07de Boer JF3 papers · 2026
Department of Pediatrics, University Medical Center Groningen, Groningen, The Netherlands.
Papers in Europe PMC - 08Dehghani SM3 papers · 2026
Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Fars Province, Iran, sums.ac.ir.
Papers in Europe PMC - 09Di Giorgio A3 papers · 2026
Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Papers in Europe PMC - 10Eğritaş Gürkan Ö3 papers · 2025
Department of Pediatric Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
13
interventional trials for this specific condition
13 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 27 July 2026
13 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 92.8th percentile).
low confidence · 92.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
13 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07317193·RECRUITING·DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE
Conditions: Cholestatic Liver Disease · Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT07290257·RECRUITING·Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
Conditions: Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
Broader category: familial intrahepatic cholestasis
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Observational and natural-history studies
16 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07191704·RECRUITING·A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain
Conditions: PFIC - Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT06781242·RECRUITING·Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
Conditions: Cholestatic Liver Disease · Intrahepatic Cholestasis · Progressive Familial Intrahepatic Cholestasis · Hepatobiliary Cancer·Matched via name phrase
- NCT06193928·RECRUITING·Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Conditions: Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT07411716·RECRUITING·Pediatric Evaluation and Registry for Liver Cholestasis in Canada
Conditions: PFIC - Progressive Familial Intrahepatic Cholestasis · Alagille Syndrome (ALGS) · Cholestasis, Intrahepatic·Matched via name phrase
- NCT03930810·ENROLLING BY INVITATION·NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion
Conditions: Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT07588880·RECRUITING·A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
Conditions: Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT07185919·RECRUITING·A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
Conditions: Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT01403402·RECRUITING·Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency · Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy) · Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations) · Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)·Matched via name phrase
- NCT06778174·RECRUITING·Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC)
Conditions: Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT07293897·RECRUITING·A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
Conditions: Alagille Syndrome (ALGS) · Progressive Familial Intrahepatic Cholestasis (PFIC)·Matched via name phrase
- NCT06777914·RECRUITING·Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers
Conditions: Hepatobiliary Cancers · Progressive Familial Intrahepatic Cholestasis (PFIC) · Cholestatic Liver Disease·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Progressive familial intrahepatic cholestasis" OR "cholestasis, progressive familial intrahepatic"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Progressive familial intrahepatic cholestasis" OR "cholestasis, progressive familial intrahepatic" OR "ABCB11" OR "ATP8B1" OR "PLEC"
Recall-expansion terms: ABCB11, ATP8B1, PLEC
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 13 interventional · 16 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"familial intrahepatic cholestasis"
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PFIC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (2892) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T12:44:34.320Z
